This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Ampio Pharmaceuticals Announces Appointment Of Gregory A. Gould As Chief Financial Officer

Stocks in this article: AMPE

GREENWOOD VILLAGE, Colo., June 5, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the appointment of Gregory A. Gould as Chief Financial Officer, Treasurer, and Corporate Secretary.  Mr. Gould, a veteran of the pharmaceutical and life sciences industry, is joining the company effective June 10 th, 2014.  Mark McGregor, the company's current CFO, will retire from Ampio Pharmaceuticals following a transition period later this year.

Ampio Pharmaceuticals Logo

Greg Gould has over eighteen years of senior management experience at public pharmaceutical and life sciences companies, where he has demonstrated success leading accounting and finance organizations, inclusive of fundraising, licensing transactions, and acquisitions.

Most recently Greg served as the Interim President and Chief Executive Officer and Chief Financial Officer of SeraCare Life Sciences, Inc. in Milford, Massachusetts.  Under Greg's leadership SeraCare completed a successful transition as a publicly traded company to a private equity firm following a successful turnaround and growth of the company's revenues, gross margins, and EBIDTA.

Prior to his time at SeraCare, Mr. Gould was the Chief Financial Officer of Atrix Laboratories, Inc. in Fort Collins, Colorado.  During Greg's tenure at Atrix he was instrumental in the negotiation and sale of the company to QLT, Inc. for over $855M. He also played a critical role in the management of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo of the Eligard ® products.

Prior to joining Atrix Greg held positions of increasing responsibility in finance and accounting at Colorado MedTech in Boulder, Colorado, a publicly traded medical device design and manufacturing company.  Mr. Gould began his career as an auditor with Arthur Andersen, LLC.  Greg currently serves on the board of directors of CytoDyn, Inc., a publicly traded drug development company pursuing ant-viral agents for the treatment of HIV.  Greg graduated from the University of Colorado with a BS in Business Administration and is a Certified Public Accountant.

Mike Macaluso, Ampio's Chairman and Chief Executive Officer stated, "We are pleased to welcome Greg to the Ampio management team.  His experience in negotiating favorable licensing and M&A transactions will be important as Ampio is completing pivotal clinical trials and preparing to commercialize our two lead drugs, Ampion TM for the treatment of Osteoarthritis of the knee (OAK) and Optina TM for the treatment of diabetic macular edema (DME).

"As we welcome Greg to the Ampio team we also thank Mark McGregor for his exceptional contributions as Chief Financial Officer over the last three years.  Under Mark's leadership, Ampio has been flawless in timely filing all required SEC reports, and he has passed on to Greg a smoothly functioning accounting operation. We wish Mark the best as he enters his well deserved retirement."

About Ampio Pharmaceuticals:Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements:Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact: April RamirezOperations CoordinatorAmpio Pharmaceuticals, Inc.Direct: (720) 437-6500Email:  aramirez@ampiopharma.com

Logo - http://photos.prnewswire.com/prnh/20120516/MM09116LOGO

SOURCE Ampio Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs